Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis

Eur Urol. 2016 Jan;69(1):9-12. doi: 10.1016/j.eururo.2015.07.004. Epub 2015 Jul 16.


The literature on metastasis-directed therapy for oligometastatic prostate cancer (PCa) recurrence consists of small heterogeneous studies. This study aimed to reduce the heterogeneity by pooling individual patient data from different institutions treating oligometastatic PCa recurrence with stereotactic body radiotherapy (SBRT). We focussed on patients who were treatment naive, with the aim of determining if SBRT could delay disease progression. We included patients with three or fewer metastases. The Kaplan-Meier method was used to estimate distant progression-free survival (DPFS) and local progression-free survival (LPFS). Toxicity was scored using the Common Terminology Criteria for Adverse Events. In total, 163 metastases were treated in 119 patients. The median DPFS was 21 mo (95% confidence interval, 15-26 mo). A lower radiotherapy dose predicted a higher local recurrence rate with a 3-yr LPFS of 79% for patients treated with a biologically effective dose ≤100Gy versus 99% for patients treated with >100Gy (p=0.01). Seventeen patients (14%) developed toxicity classified as grade 1, and three patients (3%) developed grade 2 toxicity. No grade ≥3 toxicity occurred. These results should serve as a benchmark for future prospective trials.

Patient summary: This multi-institutional study pools all of the available data on the use of stereotactic body radiotherapy for limited prostate cancer metastases. We concluded that this approach is safe and associated with a prolonged treatment progression-free survival.

Keywords: Neoplasm metastasis; Neoplasm recurrence; Oligometastasis; Prostatic neoplasms; Radiosurgery; Stereotactic body radiotherapy.

Publication types

  • Multicenter Study

MeSH terms

  • Abdominal Neoplasms / drug therapy
  • Abdominal Neoplasms / secondary
  • Abdominal Neoplasms / surgery*
  • Aged
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Bone Neoplasms / drug therapy
  • Bone Neoplasms / secondary
  • Bone Neoplasms / surgery*
  • Disease-Free Survival
  • Humans
  • Kaplan-Meier Estimate
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery*
  • Radiosurgery* / adverse effects
  • Radiotherapy Dosage
  • Retrospective Studies
  • Survival Rate


  • Androgen Antagonists
  • Antineoplastic Agents